MX2009009636A - Metodos para tratar enfermedades oftalmicas. - Google Patents

Metodos para tratar enfermedades oftalmicas.

Info

Publication number
MX2009009636A
MX2009009636A MX2009009636A MX2009009636A MX2009009636A MX 2009009636 A MX2009009636 A MX 2009009636A MX 2009009636 A MX2009009636 A MX 2009009636A MX 2009009636 A MX2009009636 A MX 2009009636A MX 2009009636 A MX2009009636 A MX 2009009636A
Authority
MX
Mexico
Prior art keywords
methods
ophthalmic diseases
treating ophthalmic
treating
inhibitors
Prior art date
Application number
MX2009009636A
Other languages
English (en)
Inventor
Chia-Yang Lin
Original Assignee
Rinat Neuroscience Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rinat Neuroscience Corp filed Critical Rinat Neuroscience Corp
Publication of MX2009009636A publication Critical patent/MX2009009636A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se describen métodos para usar inhibidores (incluyendo anticuerpos monoclonales) dirigidos contra el péptido amiloide-beta para el tratamiento de enfermedades oftálmicas tales como degeneración macular relacionada con la edad.
MX2009009636A 2007-03-09 2008-03-06 Metodos para tratar enfermedades oftalmicas. MX2009009636A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89418107P 2007-03-09 2007-03-09
US12/041,581 US20090022728A1 (en) 2007-03-09 2008-03-03 Methods of treating ophthalmic diseases
PCT/IB2008/000486 WO2008110885A2 (en) 2007-03-09 2008-03-06 Methods of treating ophthalmic diseases

Publications (1)

Publication Number Publication Date
MX2009009636A true MX2009009636A (es) 2009-12-11

Family

ID=39760152

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009636A MX2009009636A (es) 2007-03-09 2008-03-06 Metodos para tratar enfermedades oftalmicas.

Country Status (15)

Country Link
US (1) US20090022728A1 (es)
EP (1) EP2134751A2 (es)
JP (2) JP5964004B2 (es)
KR (2) KR101259225B1 (es)
CN (2) CN101687922B (es)
AU (1) AU2008224600B2 (es)
BR (1) BRPI0808711A2 (es)
CA (1) CA2680222C (es)
HK (1) HK1201046A1 (es)
IL (1) IL200528A0 (es)
MX (1) MX2009009636A (es)
NZ (1) NZ579273A (es)
RU (1) RU2434639C2 (es)
TW (1) TWI449535B (es)
WO (1) WO2008110885A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
PL1954718T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Przeciwciała skierowane przeciwko A globulomerowi, ich reszty wiążące antygeny, odpowiednie hybrydomy, kwasy nukleinowe, wektory, komórki gospodarze, sposoby wytwarzania tych przeciwciał, kompozycje zawierające te przeciwciała, zastosowania tych przeciwciał i sposoby stosowania tych przeciwciał
JP5486808B2 (ja) 2005-11-30 2014-05-07 アッヴィ・インコーポレイテッド アミロイドベータタンパク質に対するモノクローナル抗体及びその使用
PL2046833T3 (pl) 2006-07-14 2014-01-31 Ac Immune Sa Humanizowane przeciwciało przeciw amyloidowi beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
AU2015200604B2 (en) * 2007-10-05 2016-10-27 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
CN105169388A (zh) * 2007-10-05 2015-12-23 基因技术公司 人源化抗体
CN101998863B (zh) * 2007-10-05 2015-09-16 基因技术公司 抗淀粉状蛋白β抗体在眼病中的用途
RS53174B (en) 2007-10-05 2014-06-30 Genentech Inc. USE OF ANTIAMYLOID BETA ANTIBODY IN THE EVENT OF ANY DISEASE
BRPI0819916A2 (pt) 2007-12-11 2015-05-19 Glaxo Group Ltd Proteína de ligação a antígeno, composição farmacêutica, método para tratar um paciente humano afligido com uma doença, anticorpo ou fragmento do mesmo, e, proteína de ligação a antígeno.
CN104744591B (zh) 2010-04-15 2022-09-27 Abbvie德国有限责任两合公司 β淀粉样蛋白结合蛋白
WO2012016173A2 (en) 2010-07-30 2012-02-02 Ac Immune S.A. Safe and functional humanized antibodies
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
JP2014511174A (ja) * 2011-02-07 2014-05-15 ネオトープ バイオサイエンシーズ リミテッド Apoe免疫療法
RU169012U1 (ru) * 2016-08-08 2017-03-01 Дмитрий Викторович Давыдов Электрод для электростимуляции зрительного нерва и зрительных путей и контроля физиологических параметров орбитальных структур глаза
WO2018200620A1 (en) * 2017-04-25 2018-11-01 National Cheng Kung University Use of il-20 antagonists for treating eye diseases
CA3161266A1 (en) * 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004032868A2 (en) * 2002-10-09 2004-04-22 Rinat Neuroscience Corp. Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
JP2007527865A (ja) * 2003-09-12 2007-10-04 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 種々の配列を有するタンパク質から形成されたアミロイドに共通の高分子量凝集中間体に特異的なモノクローナル抗体
US20060121039A1 (en) * 2004-12-07 2006-06-08 Alcon, Inc. Use of agents that prevent the generation of amyloid-like proteins and/or drusen, and/or use of agents that promote sequestration and/or degradation of, and/or prevent the neurotoxic effects of such proteins in the treatment of macular degeneration
EP2298807A3 (en) * 2004-07-30 2011-05-18 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
WO2006039327A2 (en) * 2004-10-01 2006-04-13 Merck & Co., Inc. Methods of treatment or prophylaxis of amyloidogenic diseases of the eye or optic nerve
JP2008527005A (ja) * 2005-01-14 2008-07-24 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、カリフォルニア ドルーゼン形成を阻害するため、およびドルーゼン関連障害を診断または治療するための組成物および方法
UY29504A1 (es) * 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
DK2361638T3 (en) * 2005-12-12 2014-03-03 Ac Immune Sa Beta-1-42-specific monoclonal antibodies with therapeutic properties
PL2046833T3 (pl) * 2006-07-14 2014-01-31 Ac Immune Sa Humanizowane przeciwciało przeciw amyloidowi beta
ES2640095T3 (es) * 2006-10-02 2017-10-31 Ac Immune S.A. Anticuerpo humanizado contra beta-amiloide

Also Published As

Publication number Publication date
KR20090119990A (ko) 2009-11-23
IL200528A0 (en) 2010-04-29
US20090022728A1 (en) 2009-01-22
JP2009062358A (ja) 2009-03-26
JP2015038109A (ja) 2015-02-26
RU2009133789A (ru) 2011-03-20
KR101259225B1 (ko) 2013-04-30
TWI449535B (zh) 2014-08-21
CN101687922A (zh) 2010-03-31
AU2008224600B2 (en) 2011-09-29
KR20120054105A (ko) 2012-05-29
CA2680222A1 (en) 2008-09-18
HK1201046A1 (en) 2015-08-21
CA2680222C (en) 2013-10-08
RU2434639C2 (ru) 2011-11-27
NZ579273A (en) 2012-03-30
WO2008110885A2 (en) 2008-09-18
CN101687922B (zh) 2014-06-11
BRPI0808711A2 (pt) 2014-08-12
TW200900079A (en) 2009-01-01
WO2008110885A3 (en) 2009-01-15
JP5964004B2 (ja) 2016-08-03
AU2008224600A1 (en) 2008-09-18
EP2134751A2 (en) 2009-12-23
CN104027803A (zh) 2014-09-10

Similar Documents

Publication Publication Date Title
MX2009009636A (es) Metodos para tratar enfermedades oftalmicas.
GEP20227369B (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
SG194701A1 (en) Anti-cd40 antibodies and methods of use
MY156662A (en) Amine derivative compounds for treating ophthalmic diseases and disorders
EP2582722A4 (en) ANTIBODIES AGAINST GD2
MX2018010331A (es) Agentes de ligacion al factor de crecimiento endotelial vascular/ligando 4 similar a delta (vegf/dll4) y usos de los mismos.
IL187594A0 (en) Humanized anti-cd40 antibodies and their methods of use
NZ706377A (en) Il-6 antagonists and uses thereof
EA200802182A1 (ru) Модифицированные гуманизированные антитела против интерлейкина-18
PH12015502017A1 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune disease
SG171690A1 (en) Treatment of protein degradation disorders
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
MY149630A (en) Antibodies against amyloid-beta peptide
EA200971077A1 (ru) Гетероциклические модуляторы киназы
TN2012000555A1 (en) Antibodies to human gdf8
WO2007056540A3 (en) Tnf-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy
MX2010005651A (es) Inhibicion de receptor de proteina de estimulacion de macrofagos (ron) y sus metodos de tratamiento.
MX350355B (es) Composiciones y metodos para aumentar la masa muscular y la fuerza muscular antagonizando especificamente gdf8 y/o activina a.
MX2022008523A (es) Compuestos que interactuan con glicanos y metodos de uso.
EA201170590A1 (ru) Ингибиторы рецептора фактора роста фибробластов-3 (fgfr-3) и способы лечения
EA200970403A1 (ru) Бициклические триазолы в качестве модуляторов протеинкиназы
WO2007098122A3 (en) Methods for the treatment of macular degeneration and related eye conditions
EA201390156A1 (ru) ПРОИЗВОДСТВО ИНТЕР-АЛЬФА-ИНГИБИТОРНЫХ БЕЛКОВ (IaIp) ИЗ ПЛАЗМЫ
MY153738A (en) Sulphur-linked compounds for treating ophthalmic diseases and disorders.
AU2016348418A8 (en) Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration